Long-Term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
Kevin H.M. Kuo(University Health Network), Elliott Vichinsky(Unknown), Joy Bhatia(Agios Pharmaceuticals (United States)), Penelope A. Kosinski(Agios Pharmaceuticals (United States)), Bo Tong(AbbVie (United States)), Hanny Al‐Samkari(Harvard University), Katrin Uhlig(Tufts Medical Center), Ashutosh Lal(Post Graduate Institute of Medical Education and Research), D. Mark Layton(Imperial College Healthcare NHS Trust), Megan T. Lynch(University of Maryland, Baltimore)
Cited by 7
Related Papers
Sickle cell disease
|Nature Reviews Disease Primers|2018|1.4k
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
|Blood|2018|165
Graft Use in Transvaginal Pelvic Organ Prolapse Repair
|Obstetrics and Gynecology|2008|163
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
|New England Journal of Medicine|2019|162